Pipeline, Portfolio, and Products
Driven by a patient-first mindset, we connect technology and life-sciences expertise to propel patient-needed therapies sooner.
Pipeline **

** This list is comprised only of therapies/indications in the U.S. and does not reflect approvals outside the U.S.
* Products of Myovant, a publicly listed company, in which Sumitovant holds a majority ownership interest.
+ Licensed to third parties for development/commercialization in certain territories; for more details, visit the product websites provided below.
Portfolio Companies
Urovant
Creating innovative treatment options for people living with urologic conditions.
Enzyvant
Advancing novel regenerative therapies for pediatric rare diseases.
Myovant *
Women’s health and prostate cancer.
Spirovant
Developing gene therapies for genetic lung diseases.
Altavant
Developing therapies addressing rare respiratory diseases.
* Sumitovant holds a majority ownership interest in Myovant, a publicly listed company.
Products

To learn more about Gemtesa, visit the following website:
www.gemtesa.com
Please use the link below to download a PDF version of the following documents: Full Prescribing Information | Patient Medication Guide

To learn more about Rethymic, visit the following website:
www.rethymic.com
Please use the link below to download a PDF version of the following documents: Full Prescribing Information

To learn more about Orgovyx, visit the following website:
www.myovant.com
Please use the link below to download a PDF version of the following documents: Full Prescribing Information | Patient Medication Guide

To learn more about Myfembree, visit the following website:
www.myovant.com
Please use the link below to download a PDF version of the following documents: Full Prescribing Information | Patient Medication Guide